Navigation Links
HeartWare to Present at the Canaccord Genuity 31st Annual Growth Conference
Date:8/8/2011

FRAMINGHAM, Mass. and SYDNEY, Aug. 8, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to make an investor presentation at the Canaccord Genuity 31st Annual Growth Conference at 9:00 a.m. U.S. Eastern Time on Thursday, August 11, 2011.  The conference is being held August 9-11, 2011 at The InterContinental Hotel in Boston.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  An archived replay of the presentation will also be available shortly after the presentation time for 90 days.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010
2. HeartWare to Report Financial Results for Second Quarter of 2011
3. HeartWare to Present at the Wells Fargo 2011 Healthcare Conference
4. HeartWare to Present at the 2011 Bank of America Merrill Lynch Health Care Conference
5. HeartWare International Reports First Quarter 2011 Revenues of $18.0 Million; 68% Increase From $10.7 Million in First Quarter 2010
6. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
7. HeartWare Announces Presentations at The International Society of Heart and Lung Transplantation Annual Meeting
8. HeartWare International Receives Approval From the Therapeutic Goods Administration (TGA) in Australia
9. HeartWare to Present at the Barclays Capital 2011 Global Healthcare Conference
10. HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009
11. HeartWare Receives Third Patient Allotment From FDA - Authorizing 94 Additional Patients - Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015 Nevro Corp. (NYSE: ... has developed and commercialized an innovative, evidence-based neuromodulation platform ... Brad Vale , PhD, DVM, former Head of ... to its Board of Directors, effective March 1, 2015. ... of experience in developing, commercializing and investing in innovative ...
(Date:3/2/2015)... WEST JORDAN, Utah , March 2, 2015 ... of Medical Imaging Solutions, has acquired Eclipse Systems, ... and customized service solutions. As part of their ... comprehensive service at an affordable rate, BC Technical ... strategic acquisition allows BC Technical to add valuable ...
(Date:3/2/2015)... 2, 2015  DURECT Corporation (Nasdaq: ... and the successful completion of a Phase 1 ... DUR-928.  DUR-928 is an endogenous, small-molecule, new chemical ... metabolic diseases such as nonalcoholic fatty liver disease ... organ injuries such as acute kidney injury (AKI).  ...
Breaking Medicine Technology:Nevro Appoints Dr. Brad Vale to its Board of Directors 2BC Technical Acquires Eclipse Systems 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5
... Dec. 9, 2010 The national media keeps ringing the ... the NYU one-year research study on pediatric dosing instructions on ... the American Medical Association ,s December issue. The results are ... liquid medications, found inconsistencies across all the medications, with the ...
... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a ... with inflammation, today announced it will hold a conference ... and remediation plans relating to vial problems in the ... 2010Time: , 5:00 pm Eastern TimeDomestic Dial-in: , (877) ...
Cached Medicine Technology:AccuDial® Pharmaceutical Solves OTC Dosing Errors for Children's Liquid Medications 2AccuDial® Pharmaceutical Solves OTC Dosing Errors for Children's Liquid Medications 3Anthera Announces Update Call Regarding Vial Problems 2
(Date:3/2/2015)... Monroeville, PA (PRWEB) March 02, 2015 ... part of the Allegheny Health Network, are ... with new software called Visual Info Zonal Reminder (VIZR), ... , Introduced in 2013, Google Glass is a wearable ... in a smartphone-like hands-free format. Wearers communicate with the ...
(Date:3/2/2015)... CA (PRWEB) March 02, 2015 Ticket ... tickets at the Hollywood Bowl . This popular site ... customer appreciation promo code JIMMY-BUFFETT-2015 for added savings. , ... their favorite performer will be headlining at the Hollywood ... concert will be on Thursday, October 22nd and it ...
(Date:3/2/2015)... 02, 2015 Doctors in Novara, Italy ... better predictor of outcomes for people with mesothelioma than ... of the new study on the Surviving Mesothelioma ... University of Eastern Piedmont followed the cases of 172 ... for excess lung fluid. , “Persistent lung expansion ...
(Date:3/2/2015)... 02, 2015 Burns Engineering's Lab-to-Lab ... for Secondary Standard Platinum Resistance Thermometers (SSPRTs) and ... days or less . . . guaranteed. ... Accredited (Lab Code 200706-0), ISO 9001 and 17025 ... range is -196°C to 500°C, both ITS-90 and ...
(Date:3/2/2015)... The minimally invasive surgical instruments market ... 6.1% to reach $14,133.0 million by 2019 from ... as advantages of minimally invasive surgeries over traditional ... invasive surgeries and increasing number of surgical procedures ... minimally invasive surgical instruments market. , For More ...
Breaking Medicine News(10 mins):Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 2Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 3Health News:Cheap Jimmy Buffett Tickets Hollywood Bowl: Ticket Down Slashes Prices on Jimmy Buffett Tickets at the Hollywood Bowl in Los Angeles/Hollywood, CA 2Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2
... University may have isolated the substance most responsible// for ... a discovery that could revolututionise treatments for a host ... by Riyi Shi (REE-yee SHEE) has found that a ... high levels in spinal tissue for several days after ...
... who are being diagnosed for diabetes type 2 may ... the onset of the disease. ,A study done ... have shown that among the children who are newly ... five of them have showed tendencies of being afflicted ...
... to find out why the diabetes drug thiazolidinediones (TZDs) can ... found that the drug TZDs activates a receptor in kidney ... the collecting duct of the kidney. The activation of the ... causes edema. ,TZD drugs are generally used to lower ...
... the help of anti fungal medication itraconazole can reduce ... have broken new grounds in asthma treatment by using ... aspergillosis, which is a form of asthma. , ... with steroids or drugs that have equally disastrous side ...
... is trying new approaches to the neuroblastoma patients, researchers// ... more effective in children than the common procedure. ... that the cancer drug topotecancan must be fine tuned ... all doses are effective on everybody. Only less than ...
... placebo treatment can reduce the nature of emotional experience// ... treatment consists of dummy medication or intervention. This can ... injections etc. ,In the new research done by ... placebo treatment can effectively control the impact of negative ...
Cached Medicine News:Health News:Acrolein may be the key to halting spinal cord damage 2Health News:Acrolein may be the key to halting spinal cord damage 3Health News:Acrolein may be the key to halting spinal cord damage 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: